Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-12-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 48
- Registration Number
- NCT00194740
- Locations
- 🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
Allogeneic Transplantation From Related Haploidentical Donors
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 16
- Registration Number
- NCT00185692
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Wen-Kai Weng
- Target Recruit Count
- 63
- Registration Number
- NCT00185614
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 36
- Registration Number
- NCT00186628
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 303
- Registration Number
- NCT00185640
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00169104
Stem Cell Transplantation for Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 11
- Registration Number
- NCT00176839
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 38
- Registration Number
- NCT00148317
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00139230
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00133367
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.